Abstract:When animals learn hippocampus-dependent associative and spatial tasks such as trace eyeblink conditioning and the water maze, CA1 hippocampal neurons become more excitable as a result of reductions in the post-burst, slow afterhyperpolarization. The calcium-activated potassium current that mediates this afterhyperpolarization is activated by the calcium influx that occurs when a series of action potentials fire and serves as a modulator of neuronal firing frequency. As a result, spike frequency accommodation is also reduced after learning. Neuronal calcium buffering processes change and/or voltage-dependent calcium currents increase during aging; leading to enhancements in the slow afterhyperpolarization, increased spike frequency accommodation and age-associated impairments in learning. We describe a series of studies done to characterize this learning-specific enhancement in intrinsic neuronal excitability and its converse in aging brain. We have also combined behavioral pharmacology and biophysics in experiments demonstrating that compounds that increase neuronal excitability in CA1 pyramidal neurons also enhance learning rate of hippocampus-dependent tasks, especially in aging animals. The studies reviewed here include those using nimodipine, an L-type calcium current blocker that tends to cross the blood-brain barrier; metrifonate, a cholinesterase inhibitor; CI1017, a muscarinic cholinergic agonist; and galantamine, a combined cholinesterase inhibitor and nicotinic agonist. Since aging is the chief risk factor for Alzheimer's disease, a disease that targets the hippocampus and associated brain regions and markedly impairs hippocampus-dependent learning, these compounds have potential use as treatments for this disease. Galantamine has been approved by the USDA for this purpose. Finally, we have extended our studies to the TG2576 transgenic mouse model of Alzheimer's disease (AD), that overproduces amyloid precursor protein (APP) and increases levels of toxic beta-amyloid in the brain. Not only do these mice show deficits in hippocampus-dependent learning as they age, but their hippocampal neurons show a reduced capacity to increase their levels of intrinsic excitability with reductions in the slow afterhyperpolarization after application of the muscarinic agonist carbachol. These TG2576 APP overproducing mice were crossed with BACE1 knockout mice, that do not produce beta-amyloid because cleavage of APP by the beta-site APP cleaving enzyme 1 (BACE1) is a critical step in its formation. Not only was hippocampus-dependent learning rescued in the bigenic TG2576-BACE1 mice, but the capacity of hippocampal neurons to show normal enhancements of intrinsic excitability was restored. The series of studies reviewed here support our hypothesis that enhancement in intrinsic excitability by reductions in calcium-activated potassium currents in hippocampal neurons is an important cellular mechanism for hippocampus-dependent learning.

P4-240: Potentiation of calcium/calmodulin–dependent protein kinase I I benefits for cognitive enhancement in Alzheimer's disease patients

Galantamine Enhancement of Long‐term Potentiation is Mediated by Calcium/calmodulin‐dependent Protein Kinase II and Protein Kinase C Activation

CaM Kinase II and Protein Kinase C Activations Mediate Enhancement of Long-Term Potentiation by Nefiracetam in the Rat Hippocampal CA1 Region.

Nefiracetam activation of CaM kinase II and protein kinase C mediated by NMDA and metabotropic glutamate receptors in olfactory bulbectomized mice.

Cellular Mechanisms of Cognitive Enhancement: The In Vivo Modulation of the Firing Activity and the Responsiveness of Rat Hippocampal Neurons by Memantine and Alpha7 Nicotinic Acetylcholine Receptor Ligands

Upregulation of Calcium/Calmodulin-Dependent Protein Kinase IV Improves Memory Formation and Rescues Memory Loss with Aging

Pharmacological and molecular enhancement of learning in aging and Alzheimer's disease

Allosteric inhibition of phosphodiesterase 4D induces biphasic memory-enhancing effects associated with learning-activated signaling pathways

Improvement of Depressive Behaviors by Nefiracetam is Associated with Activation of CaM Kinases in Olfactory Bulbectomized Mice

The Role of Calcium-Dependent Desensitization in the Potentiation by Gne-9278 of NMDA Receptor Currents in Rat Cortical Neurons in vitro

CaMKII-dependent Dendrite Ramification and Spine Generation Promote Spatial Training-Induced Memory Improvement in a Rat Model of Sporadic Alzheimer's Disease.

The NMDA receptor as a target for cognitive enhancement

Modulation of Long-Term Potentiation in the Hippocampus by Pharmacological Approach： A Novel Strategy for the Development of Cognitive Enhancers

Magnesium boosts the memory restorative effect of environmental enrichment in Alzheimer's disease mice

Multifunctional Memantine Nitrate Significantly Protects Against Glutamate-Induced Excitotoxicity Via Inhibiting Calcium Influx and Attenuating PI3K/Akt/GSK3beta Pathway

Memantine Improves Cognitive Function and Alters Hippocampal and Cortical Proteome in Triple Transgenic Mouse Model of Alzheimer's Disease

Cognitive Enhancers in Theory and Practice: Studies of the Cholinergic Hypothesis of Cognitive Deficits in Alzheimer'S Disease

Memantine Inhibits Calcium-Permeable AMPA Receptors

The effect of the calcium channel blocker nimodipine on hippocampal BDNF/Ach levels in rats with experimental cognitive impairment

Potassium 2-(1-hydroxypentyl)-benzoate promotes long-term potentiation in Aβ1–42-injected rats and APP/PS1 transgenic mice

N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's disease.